Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Racecadotril combination therapy for pulmonary hypertension
ISRCTN96717546Phase 2Completed
- Sponsor
- University College London
- Start
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) comparing Racecadotril plus background sildenafil with Placebo plus background sildenafil (2 arms). Primary endpoint: Maximum percentage change from baseline in plasma atrial natriuretic peptide concentration. Started Feb 2014; status: completed.
02
Drugs
racecadotril
03
Conditions
pulmonary hypertension (PH)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ISRCTN96717546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN96717546.